Several possible studies
Story checked
Health insurance costs, 2026 enrollment, GLP-1: Morning Rounds (opens in a new tab)
statnews.com · 2026-10-22
Short answer
Several possible studiesStudy not confirmed.
Several potential source studies were identified, but no single match could be confirmed. The article's claims remain unverified.
These papers were considered as possible sources, but none could be confirmed as the study behind this story.
Share this check
The story
Health insurance costs, 2026 enrollment, GLP-1: Morning Rounds
statnews.com · 2026-10-22
The story’s checkable claims.
Read the original story (opens in a new tab)NewsLink checks it
Multiple potential source studies identified.
Several studies match details in the article, but none could be confirmed as its source. The claims have not been assessed against a source study.
View article claimsSearch result
Several studies could fit.
Several studies match details in the article, but none could be confirmed as its source. The claims have not been assessed against a source study.
Evidence layer
Claim by claim
The article's claims are listed below. Without a confirmed source study, they have not been assessed as supported or unsupported.
Reading mode
Scan verdicts. Open evidence only when needed.
Claim 1 of 2Not checkedTelehealth companies aren’t waiting for FDA approval to test popular obesity medications GLP-1s for other indications.View evidenceHide evidence
Not checked
No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.
Claim 2 of 2Not checkedTheir next target is addictions like alcohol use disorder.View evidenceHide evidence
Not checked
No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.
Method layer
Study not confirmed.
The search results are available for you to inspect. Without a confirmed source study, they cannot establish whether the story’s claims are supported or contradicted.
Search results
Candidate papers, not confirmed sources.
PubMed, Crossref, Europe PMC · 15 candidate papers
Modulating neuroinflammation with glucagon-like peptide-1 receptor agonists: a scoping review exploring their therapeutic potential in schizophrenia.
Progress in Neuro-psychopharmacology & Biological Psychiatry · 2026 · PubMed
GLP-1 Agonist Use In Patients Entering Alcohol Use Disorder Treatment
Drug and Alcohol Dependence · 2025 · Crossref
Alcohol Use Following GLP-1 Receptor Agonist Therapy in the Cooper Center Longitudinal Study.
2026 · Europe PMC
Exploring semaglutide for alcohol use disorder: A review of clinical efficacy and neurobiological mechanisms.
Addictive Behaviors · 2026 · PubMed, Europe PMC
RWD115 ASSOCIATION BETWEEN GLP-1 RECEPTOR AGONIST USE AND INCIDENT ALCOHOL USE DISORDER AMONG PATIENTS WITH DIABETES: A REAL-WORLD EVIDENCE STUDY
Value in Health · 2026 · Crossref